Wednesday, January 27, 2021


EPIX ESSA Pharma Inc. gains 138% Jan 27, 2021

ESSA Pharma Inc., a clinical-stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive